Safety of budesonide/glycopyrronium/formoterol fumarate dihydrate delivered by HFO-1234ze versus HFA-134a in chronic obstructive pulmonary disease: a phase 3, multi-site, randomised, double-blind, parallel-group, active-comparator study.

Usmani OS, Martinez FJ, Pandya H, Camiolo M, Bednarczyk A, Kucz K, Kokot M, Gottfridsson C, Aurivillius M, Pettersson L, Mei J, Skansen K, Bell JL, Petullo D, Collison K, Bondarov P, Jassal M, Patel M

Open source

DOI: 10.1016/j.eclinm.2025.103402
Published: 2025 Sep
Container: EClinicalMedicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.eclinm.2025.103402,
  title = {Safety of budesonide/glycopyrronium/formoterol fumarate dihydrate delivered by HFO-1234ze versus HFA-134a in chronic obstructive pulmonary disease: a phase 3, multi-site, randomised, double-blind, parallel-group, active-comparator study.},
  author = {Usmani OS and Martinez FJ and Pandya H and Camiolo M and Bednarczyk A and Kucz K and Kokot M and Gottfridsson C and Aurivillius M and Pettersson L and Mei J and Skansen K and Bell JL and Petullo D and Collison K and Bondarov P and Jassal M and Patel M},
  year = {2025},
  journal = {EClinicalMedicine},
  doi = {10.1016/j.eclinm.2025.103402},
  url = {https://doi.org/10.1016/j.eclinm.2025.103402}
}

RIS

TY  - JOUR
TI  - Safety of budesonide/glycopyrronium/formoterol fumarate dihydrate delivered by HFO-1234ze versus HFA-134a in chronic obstructive pulmonary disease: a phase 3, multi-site, randomised, double-blind, parallel-group, active-comparator study.
AU  - Usmani OS
AU  - Martinez FJ
AU  - Pandya H
AU  - Camiolo M
AU  - Bednarczyk A
AU  - Kucz K
AU  - Kokot M
AU  - Gottfridsson C
AU  - Aurivillius M
AU  - Pettersson L
AU  - Mei J
AU  - Skansen K
AU  - Bell JL
AU  - Petullo D
AU  - Collison K
AU  - Bondarov P
AU  - Jassal M
AU  - Patel M
PY  - 2025
JO  - EClinicalMedicine
DO  - 10.1016/j.eclinm.2025.103402
UR  - https://doi.org/10.1016/j.eclinm.2025.103402
ER  -

APA

OS, U., FJ, M., H, P., M, C., A, B., K, K., M, K., C, G., M, A., L, P., J, M., K, S., JL, B., D, P., K, C., P, B., M, J., & M, P. (2025). Safety of budesonide/glycopyrronium/formoterol fumarate dihydrate delivered by HFO-1234ze versus HFA-134a in chronic obstructive pulmonary disease: a phase 3, multi-site, randomised, double-blind, parallel-group, active-comparator study.. EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2025.103402

Source records

pubmed · retrieved 2026-09-27T12:24:52.862Z